Metoject Pen

Methotrexate, the active ingredient in Metoject Pen, is an antimetabolite presented as a pre‑filled pen for subcutaneous injection. It is used to treat rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and other autoimmune conditions.

GNH USA supplies Metoject Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential immunosuppressant for qualified healthcare providers and supporting therapeutic programs across multiple therapeutic areas. Our global logistics network ensures timely delivery and compliance with local regulatory requirements.

Methotrexate is employed in several autoimmune and oncologic disease pathways to modulate immune activity and cell proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication as part of chemotherapy protocols. - Other autoimmune conditions: provides disease control in severe inflammatory disorders such as inflammatory bowel disease.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue - Mouth sores (stomatitis) - Mild liver enzyme elevation

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Renal impairment - Severe bone marrow suppression (pancytopenia)

Use of Metoject Pen requires careful monitoring and adherence to safety guidelines. - Pregnancy: contraindicated; teratogenic risk classified as Category X. - Liver function: monitor hepatic enzymes regularly; avoid in pre‑existing liver disease. - Renal function: assess creatinine clearance before initiation and during therapy. - Blood counts: perform complete blood count monitoring to detect cytopenias. - Concomitant immunosuppressants: evaluate risk of additive immunosuppression. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes; awareness of these interactions helps prevent toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise serum levels. - Trimethoprim‑sulfamethoxazole: risk of severe bone marrow suppression. - Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely): - Penicillins and other antibiotics: may affect renal clearance. - Sulfonylureas: potential for enhanced hypoglycemia. - Alcohol: adds to hepatic stress.